StockSelector.com
  Research, Select, & Monitor Wednesday, November 22, 2017 1:27:12 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
VIVUS, Inc.$0.65($.01)(1.52%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  VIVUS, Inc. vs Medical Instruments/Supply

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.




Not only do these companies supply the typical medical instrumentation (as the name would suggest), but also the atypical. When we think of medical instrumentation, respirators, ultrasonic cleaners, and oral cameras all come to mind. What one of the companies in this category does is also provide a very unusual service, but very useful nonetheless. They manage a cellular storage databank with thousands of different cellular samples that can be used by hospitals for different purposes. Along with the cellular storage bank and the mainstream medical instruments, there are also a few companies that have a needle-free jet injection system that, since there are no needles used, virtually eliminates accidental needle pricks and the chance of contracting a bloodborne pathogen.
 Totals Company Industry
  Sales: $124.3 Mil $110,827.6 Mil
  Market Cap: $69.8 Mil $418,991.7 Mil
  Analysts Recommendation: Hold Buy

 Averages Company Industry
 Growth
  Historic Revenue: 30.2% 7.5%
  Estimated Revenue: N/A 22.0%
  Historic Earnings: N/A 35.6%
  Estimated Earnings: (152.3%) 7.4%
  Stock Price (1 Year): (48.8%) 1,406.9%
  Cash per Share: (11.8%) 423.8%
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: N/A 32.1
  Price-to-Sales: .5 N/A
  Price-to-Book: 3.8 5.1
  Dividend Yield: N/A N/A
  Market Cap: $69.8 Mil $12,696.7 Mil
  Operations
  Net Margin: 26.7% 8.1%
  Gross Margin: 91.5% 58.5%
  Return on Equity: 1.3 .0
  Return on Assets: .1 (.2)
  Balance Sheet
  Current Ratio: 6.3 3.8
  Quick Ratio: 5.9 2.9
  Cash Ratio: 5.6 2.0
  Debt-to-Equity: 15.8 2.2
  Interest Coverage: .0 (2.0)
 Technicals
  Relative-Strength Index: 36.9 N/A

 Other companies in Medical Instruments/Supply Price Market Cap
  Morgan Stanley  (MS) $49.38 $89,627.4 Mil
  Stryker Corp.  (SYK) $155.73 $59,208.5 Mil
  Becton, Dickinson & Co.  (BDX) $226.83 $51,619.7 Mil
  Boston Scientific Corporation  (BSX) $28.80 $40,150.1 Mil
  Baxter International, Inc.  (BAX) $64.25 $35,787.3 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.